On 20 Nov 2025, the stock recorded an intraday low of Rs.266.1, representing a fall of 3.11% for the day. This decline followed two consecutive sessions of gains, signalling a reversal in short-term momentum. The stock underperformed its sector by 3.01% on the same day, while the broader Sensex index opened higher and traded near a fresh 52-week high of 85,450.22 points, supported by gains in mega-cap stocks and a bullish technical setup.
Samrat Pharmachem’s current trading levels are below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a sustained downtrend. The stock’s 52-week high was Rs.479.95, highlighting a substantial gap between its peak and current price. Over the past year, the stock has generated a return of -43.25%, contrasting sharply with the Sensex’s positive 10.15% performance during the same period.
Fast mover alert! This Large Cap from Automobiles - Passeenger just qualified for our Momentum list with stellar technical indicators. Strike while the iron is hot!
- - Recent Momentum qualifier
- - Stellar technical indicators
- - Large Cap fast mover
Financial metrics for Samrat Pharmachem reveal challenges in both profitability and cash flow. The company reported operating cash flow at its lowest annual level of Rs. -10.09 crores. Quarterly figures show a PBDIT of Rs. -0.36 crores and an operating profit to net sales ratio of -0.46%, the lowest recorded in recent periods. These figures suggest that the company’s core business activities have not generated positive earnings or cash inflows in the near term.
Return on equity (ROE) stands at 2.2%, which is modest relative to industry standards. The stock’s price-to-book value ratio is 1.2, indicating a valuation premium compared to its peers’ historical averages. Despite the subdued financial performance, foreign institutional investors (FIIs) have increased their holdings this quarter, now owning 3.24% of the company’s shares.
Samrat Pharmachem’s performance over longer periods also reflects underperformance relative to broader market indices. The stock has lagged the BSE500 index over the last three years, one year, and three months, underscoring persistent challenges in generating shareholder returns. Profitability has been notably impacted, with profits falling by approximately 75.9% over the past year.
Holding Samrat Pharmachem from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
In contrast to Samrat Pharmachem’s decline, the Sensex index has demonstrated strength, trading above its 50-day moving average with the 50-day average positioned above the 200-day average, a classic bullish indicator. This divergence highlights sector-specific and company-specific factors influencing Samrat Pharmachem’s stock price.
The pharmaceutical and biotechnology sector, in which Samrat Pharmachem operates, has experienced mixed performance, with some companies benefiting from innovation and market demand, while others face pricing pressures and regulatory scrutiny. Samrat Pharmachem’s valuation and financial metrics suggest that it is currently facing headwinds that have weighed on investor sentiment and market performance.
Overall, the stock’s fall to Rs.266.1 marks a notable milestone in its recent price trajectory, reflecting a combination of subdued financial results, valuation considerations, and broader market dynamics. The company’s trading below all key moving averages and its significant underperformance relative to the Sensex and sector peers underscore the challenges it faces in regaining upward momentum.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
